Search
for

    GlossaryAndrogen Receptor Signaling (AR signaling)

    hormones like testosterone bind to receptors, influencing gene expression

    Androgen Receptor Signaling, also known as AR signaling, is a biological pathway where androgens (male hormones like testosterone) bind to androgen receptors in cells. This binding activates the receptors, which then influence the expression of specific genes, affecting various bodily functions such as hair growth, muscle development, and reproductive processes. In the context of hair, AR signaling can play a role in conditions like androgenetic alopecia (pattern hair loss).

    Related Terms

    Learn

    2 / 2 results

      learn Pyrilutamide

      highly targeted anti-androgen that might have minimal systemic effects

      learn GT20029

      research compound made to degrade androgen receptors in scalp

    Research

    5 / 1000+ results

    Community Join

    5 / 497 results

      community GT20029 and PP405 the new fin and min that we been waiting for ?

      in Chat  36 upvotes 3 weeks ago
      PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

      community Is GT20029 supposed to regrow hair as well?

      in Treatment  10 upvotes 2 years ago
      The user is considering switching from finasteride to dutasteride for hair loss. They are unsure if GT20029 can regrow hair, particularly on the temples. Another user mentions that regrowth on finasteride can take up to 2 years.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 2 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.